Worldwide clinical trials take a major hit from pandemic, with endocrine targeted tests worst hit
April 08, 2020
Clinical trial enrollment has dropped massively across the world with endocrine and cardiovascular tests being the hardest hit.
This is according to a new breakdown from Medidata (PDF), now owned by Dassault Systèmes, which aims to show by numbers how the COVID-19 pandemic has impacted global clinical trials.
The firm’s analysis of data from 4,599 studies and 182,321 study-sites shows a stark retreat: The year-on-year difference between March 2019 and March 2020 across all reported countries and targeted disease areas saw trial enrollment down around 65% on average.